Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study.

We evaluated the feasibility to correlate intra-tumour heterogeneity as visualized on 18F-FDG PET with histology for NSCLC. For this purpose we used an ex-vivo model. The procedure was feasible in all operated patients. We have shown that this method is suitable for correlating intra-tumour heterogeneity in tracer uptake with histology.

[1]  U. Tateishi,et al.  Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Michael G. Stabin,et al.  Radiation Dose to Patients from Radiopharmaceuticals , 2009 .

[3]  Sigrid Stroobants,et al.  The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer , 2007 .

[4]  V. R. McCready,et al.  FDG accumulation and tumor biology. , 1998, Nuclear medicine and biology.

[5]  T. Manabe,et al.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. , 2005, Neoplasia.

[6]  Nagara Tamaki,et al.  Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  J C Rosenwald,et al.  Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. , 2000, International journal of radiation oncology, biology, physics.

[8]  Julie Sutcliffe-Goulden,et al.  Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Paul Cumming,et al.  Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors. , 2005, International journal of radiation oncology, biology, physics.

[10]  D. Yan,et al.  Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[11]  J. Vansteenkiste,et al.  Value of FDG-PET in the management of non-small cell lung cancer. , 2003, European journal of radiology.

[12]  I. Mellinghoff,et al.  Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.

[13]  Søren M Bentzen,et al.  Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.

[14]  Ursula Nestle,et al.  Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Philippe Lambin,et al.  The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. , 2006, Cancer treatment reviews.

[16]  C Clifton Ling,et al.  Dependence of FDG uptake on tumor microenvironment. , 2005, International journal of radiation oncology, biology, physics.

[17]  R Chan,et al.  Computed tomographic-pathologic correlation of gross tumor volume and clinical target volume in non-small cell lung cancer: a pilot experience. , 2001, Archives of pathology & laboratory medicine.